Biotech and StockMarket Podcast May 31 2016… $IONS $RLYP Gold, Oil + Macros $IONs discussed here on why we took call options. Danny explains the situation there and why it’s not as bad as the market is thinking. We also…
Tag: buy-out
Video: (Updated) My Solta-Zeltiq Merger Thesis (Public Free Video)
Hi guys, Scott here with ya! Because so many people are asking me about $SLTM and what I believe is going on with them, I have made a public video for you to listen to my thesis regarding this matter.…
The Biotech Merger And Acquisition Buzz List
Merger and acquisition rumors are heard on a daily basis throughout the market. Some have merit and turn out to be true, while others turn out to be false and without merit. Today, I will cover some companies that I…
Important Upcoming Catalyst For Antares – FDA Decision Expected October 14
n a bit more deliberate than Jazz, but is coming along nicely. Antares started its royalty deals with a gel based platform, one being a royalty deal with Actavis, Inc. (NYSE: ACT) (formely Watson Pharma) for topical oxybutynin gel. Oxybutynin…
Edited: Is An Acquisition Of Solta Medical Imminent?
In my last article concerning Solta Medical Devices (SLTM), I remarked several times how I feel the company has good assets and the potential to grab significant market share in various segments. However, I do feel the company and its…
Voce Capital Pushes For Acquisition Of Solta Medical, Activist Investor David Callan Joins In
Merger and acquisition speculation is one of the most interesting and exciting elements of the stock market. Sometimes both activist institutions and private investors can leverage deals or stop deals from happening depending on how many shares they control in…
Trius Acquired Last Week, Tetraphase Could Be Next
Written by Scott Matusow, Mr.Matusow holds a position in the company featured in this article. Last week, Cubist Pharmaceuticals Inc. (CBST) agreed to buy Trius Therapeutics Inc. (TSRX) and Optimer Pharmaceuticals Inc. (OPTR) for as much as $1.62 billion. Cubist…
Video: Solta Inc. ($SLTM) Likely Acquisition:| Chart And Commentary
Solta Inc. ($SLTM) Chart And Commentary. My short term target price opinion is $3 or so. Commentary also included.
4 Top Small Cap Biotech Acquisition Targets
Today, I list small cap companies I believe are top acquisition targets for large pharma. I combine speculation, rumors and buzz I am hearing, and company financial position as a few factors for consideration. Buy-outs are hard to predict in…
Valeant Acquires Obagi, Which Biotechs Are Next?
Yesterday, Obagi Medical Products (OMPI) was acquired by Valeant Pharmaceuticals (VRX) for $19.75 a share in an all cash deal. Last summer I covered in depth, acquisition rumors regarding Obagi. At the time, good private sources of mine confirmed that…